Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypes

Development of CoMFA models of affinity and selectivity to angiotensin II type-1 and type-2 receptors

The renin-angiotensin system (RAS) is of major importance in cardiovascular and renal regulation and has been an attractive target in drug discovery for a long time. The main receptors involved in the RAS are the Angiotensin type-1 (AT(1)) and type-2 (AT(2)) receptors, which are both activated by the endogenous octapeptide angiotensin II (AngII). This study describes the development of 3D-QSAR models for AT(1) and AT(2) receptor affinity and AT(1)/AT(2) receptor selectivity using CoMFA. A data set of 244 compounds, based on the triazolinone and quinazolinone structural classes was compiled from the literature. Before CoMFA could be performed, an alignment rule for the two structural classes was defined using the pharmacophore-searching program DISCOtech. Models were validated using a test set obtained by dividing the data set into a training set and test set using hierarchical clustering, based on the CoMFA fields, AT(1)-, AT(2)-receptor affinities, and AT(1)/AT(2) selectivity values. Predictive models with good statistics could be developed both for AT(1) and AT(2) receptor affinity as well as selectivity towards these receptors.

Manipulation of N,O-Nucleophilicity: Efficient Formation of 4-N-Substituted 2,4-Dihydro-3H-1,2,4-Triazolin-3-ones

A new efficient two-step synthesis of 2,4-dihydro-3H-1,2,4-triazolin-3-ones (triazolinones) from readily available amines is reported. Our novel conditions using hexamethyl disilazane, bromotrimethylsilane, and a catalytic amount of ammonium sulfate smoothly cyclize 1-formyl and 1-acetyl semicarbazides to the target triazolinones. This transformation features simultaneous manipulation of N- and O-nucleophilicity as well as differentiation of the nucleophilicity of a urea and an acyl carbonyl.

3-D QSAR studies of triazolinone based balanced AT1/AT2 receptor antagonists

Essential structural and physicochemical requirements in terms of common biophoric sites (pharmacophore) and secondary sites for binding and interacting with AT1 and AT2 receptors have been identified using APEX-3-D expert system on 16 N2- aryl triazolinone biphenyl sulphonamides. Among several biophoric 3-D QSAR models two models (Nos. 1 and 2) having R2 > 0.7, chance <0.05 and match >0.5 and two models (Nos. 3 and 4) having R2 > 0.89, chance <0.03 and match >0.5 with three biophoric sites and two secondary sites (except model No. 4 with three secondary sites) describe the variation in AT1 and AT2 antagonistic activities, respectively.

Angiotensin II receptor antagonism: losartan - sites and mechanisms of action

This review surveys the basic pharmacology of angiotensin II receptors and their antagonism; reviews the existing clinical experience with losartan, the first approved nonpeptide angiotensin II antagonist; suggests other possible clinical areas for angiotensin II receptor antagonism; and compares angiotensin-converting enzyme inhibition with angiotensin receptor antagonism.